

Mérieux Equity Partners acquires a majority stake in curea medical, a fast-growing manufacturer of advanced wound dressings based in Germany through a carve-out from McAirlaid's Vliesstoffe

Paris, France - March 21st, 2025 - Mérieux Equity Partners ("MxEP") is pleased to announce the acquisition of a majority stake in curea medical ("the Company" or "curea"), a carve-out from McAirlaid's, through its Buyout fund, Mérieux Participations 4 ("MP4"). This investment aims to support curea medical's continued growth and innovation in advanced wound care solutions while expanding its global reach. McAirlaid's and Management will (re)invest alongside MxEP.

Headquartered in Steinfurt (with operations based in Heilbad Heiligenstadt), Germany, curea medical has established itself as a key player in the advanced wound dressing sector, catering to homecare providers, hospitals, and pharmacies across Europe, with Germany as its core market. The Company benefits from the proprietary SuperCore® superabsorbent technology, widely regarded as a benchmark in modern wound care for superior exudate management. Compared to conventional foam dressings, curea's superabsorbent dressings offer significantly enhanced absorption and retention capacity, providing superior patient outcomes.

Founded in 2010 and with more than 50 employees, curea medical has demonstrated consistent and robust growth, achieving double-digit annual organic revenue growth rates in recent years. This performance is driven by favorable market trends and the Company's distinctive niche positioning as specialist provider of advanced wound care dressings.

Mérieux Equity Partners is acquiring a majority stake in curea medical through a primary LBO. As part of the transaction, McAirlaid's will reinvest a portion of its proceeds, as well as the Management team, including CEO Dr. Andreas Bolz, who will invest alongside McAirlaid's and MxEP. MxEP's involvement will reinforce curea medical's growth strategy by leveraging its industry expertise and extensive network to strengthen the Company's market position and accelerate geographic expansion, aiming to position curea medical as a leading European provider in superabsorbent wound dressings.

Dr. Andreas Bolz, CEO at curea medical: "Over the past 10 years, curea medical has developed into an established manufacturer of wound dressings for the German and several international markets. To take this development to the next level, we have spent the past few months searching for a new "future partner" who can provide excellent support for our next steps. We have found this partner in MxEP, and I am very much looking forward to our continued collaboration."

Alexander Maksimow, Founder and Member of the Board, McAirlaid's Vliesstoffe: "McAirlaid's is excited to have found such a strong partner in MxEP who will support curea's continuing success – especially in the international arena – with their demonstrated expertise and resources. As an airlaid specialist, we are happy to continue to support MxEP as they further develop the curea success story while returning to our core competence in airlaid production for the Food packaging and hygiene industries."

Jaana Grüter and Theodor Wuppermann, Partners at MxEP: "We are thrilled to partner with curea medical and its Management team, as well as McAirlaid's, to propel the Company into its next growth phase. curea stands out for its cutting-edge solutions in advanced wound care, and we see significant growth potential to develop its activity across Europe. Our ambition is to build a leading European

player in superabsorbent dressings, capitalizing on curea's technological expertise and state-of-the-art manufacturing capabilities located in Germany."

The investment in curea represents the tenth transaction of MP4 (the latest Private Equity investment vehicle of Mérieux Equity Partners, closed at c.€570m) and its first investment in Germany. MxEP continues to demonstrate its commitment to fostering innovation across Europe in healthcare and healthcare-related industries.

About curea medical - www.curea-medical.de

Curea medical is a German manufacturer specializing in innovative wound care solutions, particularly superabsorbent dressings that enhance healing through superior fluid management. Leveraging the proprietary SuperCore® technology, curea provides advanced products that significantly improve patient outcomes. The company serves homecare providers, pharmacies and hospitals. Its commitment to continuous growth, product innovation, and high-quality manufacturing has positioned curea as a key player in the advanced wound care sector.

About Mérieux Equity Partners - www.merieux-partners.com

Founded in 2009, Mérieux Equity Partners ("MxEP") is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM.

About McAirLaid's - www.mcairlaids.net

McAirLaid's is a pioneering manufacturer of *adhesive and binderfree* airlaid nonwovens, specializing in high-performance absorbent materials for diverse applications, including healthcare, food packaging, and hygiene products. Founded in 1997, the company has built a reputation for innovation and sustainability, developing chemical-free, highly absorbent solutions that set new industry standards.

List of participants

- **curea medical:** Dr. Andreas Bolz
- **McAirLaid's:** Alexander Maksimow, Nicol Deipenbrock
- **Mérieux Equity Partners:** Jaana Grüter, Theodor Wuppermann, Guillaume Martignoni, Leo Reimann

Buy-side advisors

- **Legal & ESG:** DLA Piper (Lars Jessen, Moritz von Hesberg, Daniel Osmanovic, Sven Bischoff)
- **Commercial:** BDO (Gurpal Ahluwalia, David Wentholt, Sam Harraden)
- **Financial, Tax, and Operational:** Alvarez & Marsal (Sébastien Catteau, Camille Peyre, Nina Fruehauf, Andre Kieviet)

Sell-side advisors

- **Financial advisor:** Carlsquare
- **Legal advisor:** Taylor Wessing

Press contacts

- **Dr. Andreas Bolz**, CEO of curea medical - andreas.bolz@curea-medical.de
- **Jean Chatillon**, Investor Relations Director - jean.chatillon@merieux-partners.com
- **Jaana Grüter**, Partner at MxEP - jaana.gruter@merieux-partners.com
- **Theodor Wuppermann**, Partner at MxEP - theodor.wuppermann@merieux-partners.com